NDUFB9 Recombinant Monoclonal Antibody

NDUFB9, also known as Complex I-B22 subunit or LYRM3, is an essential component of mitochondrial Complex I, the largest enzyme of the oxidative phosphorylation system. As part of the NADH-ubiquinone oxidoreductase complex, NDUFB9 plays a critical role in cellular energy metabolism and electron transport chain function. This makes it a valuable target for researchers investigating mitochondrial disorders, metabolic dysfunction, and the bioenergetic alterations that characterize many disease states including cancer.

This recombinant monoclonal antibody, generated from clone 4D7 in rabbit host, offers the reproducibility and consistency that demanding research applications require. Because the antibody sequence is defined and produced recombinantly, you can expect reliable performance across experiments and over time, eliminating the lot-to-lot variability that can complicate long-term studies or multi-site collaborations.

Validation data demonstrates robust performance across multiple experimental platforms. In western blot applications, this antibody detects a clean band at the expected 22 kDa molecular weight across a diverse panel of human cell lines including MCF-7, PC-3, K562, HepG2, HeLa, A549, and HEK293, as well as rat stomach tissue lysate, confirming cross-species reactivity between human and rat samples. For immunohistochemistry, the antibody has been validated in paraffin-embedded human melanoma cancer and stomach tissue sections using standard citrate buffer antigen retrieval protocols.

Whether you are exploring mitochondrial dysfunction in cancer biology, investigating metabolic reprogramming, or characterizing Complex I assembly and function, this antibody provides a dependable tool for detecting NDUFB9 across multiple sample types and experimental workflows.